Shanghai Fosun Pharmaceutical's subsidiary's injection solution of hydroxylamine tartrate has obtained drug registration approval.

Shanghai Fosun Pharmaceutical (600196.SH) announced that its holding subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., has recently received approval from the National Medical Products Administration for the listing registration application of the injection of tartaric acid metaraminol (referred to as "the drug"). This drug is a chemical drug independently developed by the group (i.e. the company and its holding subsidiaries/units). The drug is mainly used for (1) preventing and treating acute hypotension during neuraxial anesthesia; (2) assisting symptomatic treatment of hypotension caused by bleeding, drug allergies, surgical complications, head trauma or shock related to brain tumors; (3) hypotension caused by cardiogenic shock or sepsis.